Literature DB >> 29781371

Quantification of tantalum sedimentation rates in liquid embolic agents.

J R Mason1, C Dodge2, G Benndorf1,3,4.   

Abstract

Background Endovascular treatment (EVT) of brain arteriovenous malformations has evolved from cyanoacrylate derivatives such as N-butyl cyanoacrylate, an adhesive glue, to ethylene vinyl copolymer-based liquid embolics such as Onyx® and SQUID® dissolved in dimethyl sulfoxide. Although these agents offer several advantages, their rapidly decreasing radiopacity, as a result of the sedimentation of tantalum powder, compromises visual control during EVT. This study aims to quantify and compare tantalum sedimentation rates of several liquid embolic agents, and determine their effects on radiopacity. Methods The rate of sedimentation of liquid embolics Onyx 18®, SQUID 12®, and SQUID 18® was measured after preparation by single x-ray exposures for a period of 30 minutes. The signal-to-noise ratios (SNRs) of the suspension of each liquid embolic was calculated at various time points as tantalum settled out of the suspension. Precipitating Hydrophobic Injectable Liquid (PHIL®) was imaged as a control. Results Onyx 18® demonstrated the fastest sedimentation rate of the liquid embolics analyzed and demonstrated a threefold faster drop in SNR compared to SQUID 18® over 30 minutes. Onyx 18® demonstrated a one and a half times faster drop in SNR compared to SQUID 12®. Although PHIL 25® maintained constant SNR over the same time, it was lower at baseline immediately after preparation compared to tantalum-based liquids. Conclusion Caution during long injections using tantalum-based agents is advised. Onyx 18® has a significantly faster drop in radiopacity compared to SQUID 12® and SQUID 18®. Covalently bonded iodine-based embolics like PHIL® demonstrate constant radiopacity over time.

Entities:  

Keywords:  Liquid embolics; Onyx 18®; PHIL 25®; SQUID 12®; SQUID 18®; brain arteriovenous malformations; image quality; sedimentation; tantalum

Mesh:

Substances:

Year:  2018        PMID: 29781371      PMCID: PMC6116121          DOI: 10.1177/1591019918773443

Source DB:  PubMed          Journal:  Interv Neuroradiol        ISSN: 1591-0199            Impact factor:   1.610


  18 in total

1.  Microcatheter entrapment retrieval from Onyx embolization in brain arteriovenous malformations: A technical note.

Authors:  Phat D Vu; Arthur A Grigorian
Journal:  Interv Neuroradiol       Date:  2015-07-31       Impact factor: 1.610

Review 2.  Endovascular therapeutic embolisation: an overview of occluding agents and their effects on embolised tissues.

Authors:  Romaric Loffroy; Boris Guiu; Jean-Pierre Cercueil; Denis Krausé
Journal:  Curr Vasc Pharmacol       Date:  2009-04       Impact factor: 2.719

3.  Influence of temperature on embolisation with cyanoacrylate.

Authors:  S Bracard; J M Macho-Fernández; X Wang; R Anxionnat; L Picard
Journal:  Interv Neuroradiol       Date:  2001-05-15       Impact factor: 1.610

Review 4.  The use of cyanoacrylate adhesives in peripheral embolization.

Authors:  J S Pollak; R I White
Journal:  J Vasc Interv Radiol       Date:  2001-08       Impact factor: 3.464

5.  Microsurgical retrieval of an endovascular microcatheter trapped during Onyx embolization of a cerebral arteriovenous malformation.

Authors:  Brian P Walcott; Jason L Gerrard; Raul G Nogueira; Brian V Nahed; Anna R Terry; Christopher S Ogilvy
Journal:  J Neurointerv Surg       Date:  2010-10-05       Impact factor: 5.836

Review 6.  Onyx: a unique neuroembolic agent.

Authors:  Michael Ayad; Eric Eskioglu; Robert A Mericle
Journal:  Expert Rev Med Devices       Date:  2006-11       Impact factor: 3.166

7.  Embolization of arteriovenous malformations with peripheral aneurysms using ethylene vinyl alcohol copolymer. Report of three cases.

Authors:  T Terada; Y Nakamura; K Nakai; M Tsuura; T Nishiguchi; S Hayashi; T Kido; W Taki; H Iwata; N Komai
Journal:  J Neurosurg       Date:  1991-10       Impact factor: 5.115

8.  Radiation dose and image quality for paediatric interventional cardiology.

Authors:  E Vano; C Ubeda; F Leyton; P Miranda
Journal:  Phys Med Biol       Date:  2008-07-08       Impact factor: 3.609

9.  Preliminary experience with Precipitating Hydrophobic Injectable Liquid (PHIL) in treating cerebral AVMs.

Authors:  Edgar A Samaniego; Vladimir Kalousek; German Abdo; Santiago Ortega-Gutierrez
Journal:  J Neurointerv Surg       Date:  2016-01-27       Impact factor: 5.836

10.  In Vitro Quantification of the Radiopacity of Onyx during Embolization.

Authors:  Yuan Yuan Jiang; Ye-Eun Jo; Jung Min Woo; Ok Kyun Lim; Changmo Hwang; Jun Young Maeng; Jieun Kim; Namkug Kim; Deok Hee Lee
Journal:  Neurointervention       Date:  2017-03-06
View more
  4 in total

1.  Pre-operative direct puncture embolization of head and neck hypervascular tumors using SQUID 12.

Authors:  Alessandro Pedicelli; Emilio Lozupone; Iacopo Valente; Francesco Snider; Mario Rigante; Francesco D'Argento; Andrea Alexandre; Giuseppe Garignano; Luigi Chiumarulo; Gaetano Paludetti; Cesare Colosimo
Journal:  Interv Neuroradiol       Date:  2019-12-19       Impact factor: 1.610

2.  Imaging Artifacts of Liquid Embolic Agents on Conventional CT in an Experimental in Vitro Model.

Authors:  N Schmitt; R O Floca; D Paech; R A El Shafie; F Seker; M Bendszus; M A Möhlenbruch; D F Vollherbst
Journal:  AJNR Am J Neuroradiol       Date:  2020-11-19       Impact factor: 3.825

3.  Imaging Artifacts of Nonadhesive Liquid Embolic Agents in Conventional and Cone-beam CT in a Novel in Vitro AVM Model.

Authors:  Niclas Schmitt; Ralf O Floca; Daniel Paech; Rami A El Shafie; Ulf Neuberger; Martin Bendszus; Markus A Möhlenbruch; Dominik F Vollherbst
Journal:  Clin Neuroradiol       Date:  2021-04-14       Impact factor: 3.649

Review 4.  Glue, Onyx, Squid or PHIL? Liquid Embolic Agents for the Embolization of Cerebral Arteriovenous Malformations and Dural Arteriovenous Fistulas.

Authors:  Dominik F Vollherbst; René Chapot; Martin Bendszus; Markus A Möhlenbruch
Journal:  Clin Neuroradiol       Date:  2021-07-29       Impact factor: 3.649

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.